IL145834A0 - Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension - Google Patents

Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension

Info

Publication number
IL145834A0
IL145834A0 IL14583400A IL14583400A IL145834A0 IL 145834 A0 IL145834 A0 IL 145834A0 IL 14583400 A IL14583400 A IL 14583400A IL 14583400 A IL14583400 A IL 14583400A IL 145834 A0 IL145834 A0 IL 145834A0
Authority
IL
Israel
Prior art keywords
nucleic acid
acid encoding
pulmonary hypertension
angiogenic factor
treating pulmonary
Prior art date
Application number
IL14583400A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9905272A external-priority patent/FR2792531B1/fr
Application filed by Aventis Pharma Sa, Inst Nat Sante Rech Med filed Critical Aventis Pharma Sa
Publication of IL145834A0 publication Critical patent/IL145834A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL14583400A 1999-04-26 2000-04-21 Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension IL145834A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9905272A FR2792531B1 (fr) 1999-04-26 1999-04-26 Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire
US13973499P 1999-06-18 1999-06-18
PCT/FR2000/001060 WO2000065043A1 (fr) 1999-04-26 2000-04-21 Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire

Publications (1)

Publication Number Publication Date
IL145834A0 true IL145834A0 (en) 2002-07-25

Family

ID=26234932

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14583400A IL145834A0 (en) 1999-04-26 2000-04-21 Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension

Country Status (17)

Country Link
US (1) US20020086004A1 (ko)
EP (1) EP1173564A1 (ko)
JP (1) JP2002543097A (ko)
KR (1) KR20020001846A (ko)
CN (1) CN1376197A (ko)
AU (1) AU782833B2 (ko)
BR (1) BR0010034A (ko)
CA (1) CA2370404A1 (ko)
CZ (1) CZ20013813A3 (ko)
HU (1) HUP0200961A3 (ko)
IL (1) IL145834A0 (ko)
MX (1) MXPA01010849A (ko)
NO (1) NO20015223L (ko)
NZ (1) NZ515233A (ko)
PL (1) PL351114A1 (ko)
SI (1) SI20750A (ko)
WO (1) WO2000065043A1 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
US7223724B1 (en) * 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
MXPA02003434A (es) * 2000-08-04 2002-09-02 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
DK1385864T3 (da) * 2001-04-13 2010-08-16 Human Genome Sciences Inc Anti-VEGF-2-antistoffer
WO2002083849A2 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
KR100697321B1 (ko) * 2005-07-27 2007-03-20 박기랑 ＶＥＧＦ－Ａ, ＶＥＧＦ－Ｂ 및 ＶＥＧＦ－Ｃ의 안티센스ｃＤＮＡ를 함유하는 재조합 아데노-연관바이러스（ｒＡＡＶ） 및 이를 함유하는 대장암, 방광암및/또는 폐암 특이적 유전자 치료제
RU2558794C2 (ru) * 2009-06-25 2015-08-10 Байолидерс Корпорейшн Адъювантная композиция, содержащая наночастицы поли-гамма-глутаминовой кислоты-хитозан
CN105833248A (zh) * 2016-04-27 2016-08-10 温州医科大学附属第医院 成纤维细胞生长因子21的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717495B1 (fr) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
AU2051297A (en) * 1996-02-15 1997-09-02 Chiron Corporation Gene therapy method using fgf-5
EP0941116B1 (en) * 1996-11-01 2005-01-19 Ark Therapeutics Limited Use of vegf for the manufacture of a medicament for the treatment or prevention of intimal hyperplasia and delivery device
WO1998037185A2 (en) * 1997-02-20 1998-08-27 The Board Of Regents Of The University Of Texas System Vectors for controlled gene expression
US6423751B1 (en) * 1998-07-14 2002-07-23 The Brigham And Women's Hospital, Inc. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization

Also Published As

Publication number Publication date
JP2002543097A (ja) 2002-12-17
HUP0200961A3 (en) 2004-11-29
PL351114A1 (en) 2003-03-24
CZ20013813A3 (cs) 2002-02-13
NO20015223D0 (no) 2001-10-25
BR0010034A (pt) 2002-01-15
MXPA01010849A (es) 2002-11-07
WO2000065043A1 (fr) 2000-11-02
HUP0200961A2 (hu) 2002-07-29
AU4301700A (en) 2000-11-10
SI20750A (sl) 2002-06-30
AU782833B2 (en) 2005-09-01
NZ515233A (en) 2004-08-27
CA2370404A1 (fr) 2000-11-02
KR20020001846A (ko) 2002-01-09
NO20015223L (no) 2001-10-25
CN1376197A (zh) 2002-10-23
US20020086004A1 (en) 2002-07-04
EP1173564A1 (fr) 2002-01-23

Similar Documents

Publication Publication Date Title
IL223344A (en) Adno recombinant virus with a shell containing the hexane protein adpan6 and its uses
IL130899A0 (en) Adenoviruses having altered hexon proteins
HUP0203555A3 (en) Method for measuring degree and homogeneity of alumina calcination
FI971613A (fi) Defektiivisiä adenoviruksia, jotka käsittävät terapeuttisen geenin ja immunoprotektiivisen geenin
HK1036219A1 (en) Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
IL145834A0 (en) Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension
IL131209A0 (en) Recombinant haloaliphatic dehalogenases
NO995242L (no) Adenovirusmediert intratumoravlevering av en angiogeneseantagonist for behandling av tumorer
ID20580A (id) Kaca kalsium-natrium oksida hijau tua
IL114982A0 (en) Use of a defective recombinant adenovirus in gene therapy
SG108226A1 (en) Eliminate reassigned sectors
DK1152998T3 (da) Magnesiumoxid-partielstabiliseret zirkoniumoxid med høj styrke
EP1197556A4 (en) USEFUL POLYPEPTIDE
NO993465L (no) Adenoviral-vektor-formidlet gentransport inn i medulaere motoriske neuroner
GB9718487D0 (en) Pulmonary hypertension
HK1048495A1 (zh) 脫氧核糖核酸編碼的prost07多肽
AU6995200A (en) Adenoviral vectors including dna sequences encoding angiogenic inhibitors
HUP0203801A3 (en) Recombinant adenoviruses preparation and adenovirus banks
EP1179540A4 (en) NEW POLYPEPTIDES
FR2792531B1 (fr) Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire
AU3757200A (en) Treatment of pulmonary hypertension
GB9925970D0 (en) Treatment of pulmonary hypertension
GB9923888D0 (en) Novel polypeptide
GB9919097D0 (en) Ellipsometer
FR2791999B1 (fr) Composition destinee a la conservation d'adenovirus recombinants infectieux